| Autor: |
Ohtake, Takayasu, Sato, Motoyoshi, Nakazawa, Ryoichi, Kondoh, Morihiro, Miyaji, Takehiko, Moriya, Hidekazu, Hidaka, Sumi, Kobayashi, Shuzo |
| Zdroj: |
Therapeutic Apheresis & Dialysis; Feb2014, Vol. 18 Issue 1, p1-8, 8p |
| Abstrakt: |
The effect of the prostaglandin I2 analog, beraprost sodium ( BPS), on hemodialysis ( HD) patients with peripheral arterial disease ( PAD) has not been fully elucidated. The effect of BPS was compared to that of PAD drugs in HD patients with PAD in a multicenter randomized prospective interventional pilot study ( J-PADD). Seventy-two PAD patients on HD were entered and randomly divided into two groups; that is, BPS group (Group A: n = 35) and PAD drug (cilostazol or sarpogrelate) group ( Group B: n = 37). Primary endpoint was changes in skin perfusion pressure ( SPP). Kidney Disease Quality of Life ( KDQOL) score, cardiovascular events, PAD events, and adverse events were also evaluated. SPP increased significantly in both groups at 24 weeks from their basal levels. The absolute increase of SPP in Group A and Group B were 15.4 ± 30.0 mm Hg ( P < 0.0001) and 20.2 ± 22.1 mm Hg ( P = 0.025) (instep), and 13.8 ± 19.3 mm Hg ( P < 0.0001) and 9.2 ± 16.3 mm Hg ( P = 0.041) (sole), respectively. Changes of KDQOL score showed significantly better result in the role of physical score in Group A compared with Group B. Although heart rate was unchanged in Group A, 9.3/min increase was seen in Group B patients who received cilostazol. There was no intergroup difference in cardiovascular events and/or PAD events between the two groups during the study period. This exploratory pilot study suggested BPS was as effective as anti-platelet drugs in improving microcirculation in HD patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text